Sud Agarwal (CEO)

MB ChB (UK), BSc (Hons)
FANZCA (Royal Melbourne Hospital)

Dr. Agarwal is one of Australia’s foremost experts in medicinal cannabis, with key medical director and clinical positions at several leading cannabis companies. He is the chairman and CEO of Cannvalate and has been spearheading Australian-based research collaborations since early 2019.

Dr. Agarwal is leading MCRC as the CEO and is guiding regional and international research partnerships.

Darryl Davies (COO)

BSc (Hons)

Darryl is a Medicinal cannabis industry early adopter with over 15 years experience in Healthcare/Harm Minimisation. Darryl is on the Board of Directors for Cannvalate and works closely with top-tier global cannabis companies. He also hosted multi-award winning Cannabis Educational Events having established Australia’s first University led cannabis leadership program.

Julian Azzopardi (CGO)

BSc Chemistry, D Health Science

Julian has 20 yrs experience leading organisations and projects  in Australia, New Zealand, USA, Canada, LATAM, Middle East and Asia. Julian’s experience spans across healthcare, technology and Defence sectors. Julian is the driving force within the MCRC establishing the controls and creating strategic  partnerships ensuring compliance, quality and efficiency is maintained.

Adj. Prof. Con Stough (CSO)

BSc(Hons), PhD (University of Adelaide)

Adj. Prof. Stough’s research aims towards a better understanding of the cognitive and psychological effects of pharmacologically active substances ranging from illicit drugs to herbal and nutrient medicines. His research interests include: drugs and driving, and the effect of illicit drugs and alcohol on psychological and cognitive outcomes. He has published extensively in this area, through both national and international collaborations.

Dr. Gal Wong (CMO)


Dr. Wong is one of Australia’s most experienced prescribers of medicinal cannabis, and has been treating patients in this field since 2018.  He has extensive knowledge of the complex clinical regulatory issues unique to Australia, and has been training doctors and clinical staff in the overall management of cannabis treatment. Dr. Wong brings aboard his comprehensive experience of medicinal cannabis to clinical trials and research.

Strategic Assessment Workshop (SAW) Panel

The Strategic Assessment Workshop consists of four in-house MCRC specialists providing the following input:

  • Regulatory Affairs – Design an effective and efficient TGA, FDA, EMA regulatory pathway
  • Medical Affairs – Medical feasibility and patient experience
  • Clinical Research – Trial design and outcomes
  • Commercialisation – Market viability of your product

The workshop was assembled to develop the Sponsor’s research idea into a robust and pre-validated Clinical trial or clinical program. The SAW expert panel works through the four inputs with the Sponsor’s key personnel, providing a SAW Report detailing each pathway.